HUTCHMED (China) (HKG:0013) said it will receive a $10 million milestone payment from its partner Takeda Pharmaceutical (TYO:4502), which received a national reimbursement recommendation in Spain in December 2024, according to a Friday filing with the Hong Kong Stock Exchange.
The national reimbursement Takeda received is the first in Europe and relates to Fruzaqla (fruquintinib) for patients with previously treated metastatic colorectal cancer, the filing said.
Outside of China, Macau, and Hong Kong, Takeda has the exclusive worldwide license to develop further, commercialize, and manufacture fruquintinib, which treats colorectal cancer, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。